Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1288-1296

  Watters, Rebecca J ^a   Fox, Todd E ^b   Tan, Su Fern ^a   Shanmugavelandy, Sriram ^b   Choby, Jacob E ^a   Broeg, Kathleen ^a   Liao, Jason ^a   Kester, Mark ^a,b   Cabot, Myles C ^c   Loughran, Thomas P ^a   Liu, Xin ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Ceramide; Glucosylceramide; NK LGL leukemia; PPMP

Indexed keywords

1 PHENYL 2 PALMITOYLAMINO 3 MORPHOLINO 1 PROPANOL; C6 CERAMIDE NANOLIPOSOME; CERAMIDE DERIVATIVE; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; LIPOSOME; PROTEIN MCL 1; SURVIVIN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE;

AGGRESSIVE NK CELL LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL VIABILITY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; LIPIDOMICS; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TARGET CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GLUCOSYLTRANSFERASES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LIPOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MORPHOLINES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 84877734277     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.752485     Document Type: Article

References (45)

1. Alekshun TJ, Sokol L . Diseases of large granular lymphocytes. Cancer Control 2007; 14 : 141 - 150.
2. Zhang R, Shah MV, Loughran TP Jr . The root of many evils: Indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol 2010; 28 : 105 - 117.
3. Chan WC, Link S, Mawle A, et al . Heterogeneity of large granular lymphocyte proliferations: Delineation of two major subtypes . Blood 1986; 68 : 1142 - 1153.
4. L amy T, L oughran T P Jr. H ow I treat LGL leukemia. B lood 2011; 117 : 2764 - 2774.
5. Shah MV, Zhang R, Irby R, et al . Molecular profi ling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes . Blood 2008; 112: 770- 781.
6. Birbes H, El Bawab S, Obeid LM, et al . Mitochondria and ceramide: Intertwined roles in regulation of apoptosis . Adv Enzyme Regul 2002; 42 : 113 - 129.
7. B ourbon N A, Y un J, K ester M. C eramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex . J Biol Chem 2000; 275: 35617- 35623.
8. H ofmann K, D ixit V M. C eramide in apoptosis-does it really matter? Trends Biochem Sci 1998; 23 : 374 - 377.
9. Kolesnick RN, Kronke M . Regulation of ceramide production and apoptosis . Annu Rev Physiol 1998; 60: 643- 665.
10. Lin X, Fuks Z, Kolesnick R . Ceramide mediates radiation-induced death of endothelium . Crit Care Med 2000; 28(Suppl.): N87- N93.
11. B leicher R J, C abot M C. G lucosylceramide synthase and apoptosis. Biochim Biophys Acta 2002; 1585 : 172 - 178.
12. Abe A, Inokuchi J, Jimbo M, et al . Improved inhibitors of glucosylceramide synthase . J Biochem 1992; 111 : 191 - 196.
13. Kester M, Kolesnick R . Sphingolipids as therapeutics . Pharmacol Res 2003; 47: 365- 371.
14. Messner MC, Cabot MC . Glucosylceramide in humans . Adv Exp Med Biol 2010; 688 : 156 - 164.
15. Chapman JV, Gouaze-Andersson V, Messner MC, et al . Metabolism of short-chain ceramide by human cancer cells-implications for therapeutic approaches . Biochem Pharmacol 2010; 80: 308- 315.
16. X ie P, S hen Y F, S hi Y P, et a l. O verexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 2008; 32: 475- 480.
17. Barth BM, Cabot MC, Kester M . Ceramide-based therapeutics for the treatment of cancer . Anticancer Agents Med Chem 2011; 11 : 911 - 919.
18. Gouaze-Andersson V, Cabot MC . Sphingolipid metabolism and drug resistance in hematological malignancies . Anticancer Agents Med Chem 2011; 11 : 891 - 903.
19. Liu X, Ryland L, Yang J, et al . Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia . Blood 2010; 116 : 4192 - 4201.
20. Stover TC, Sharma A, Robertson GP, et al . Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma . Clin Cancer Res 2005; 11 : 3465 - 3474.
21. T ran M A, S mith C D, K ester M, et a l. C ombining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development . Clin Cancer Res 2008; 14 : 3571 - 3581.
22. Stover T, Kester M . Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells . J Pharmacol Exp Ther 2003; 307 : 468 - 475.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purifi cation. Can J Biochem Physiol 1959; 37: 911- 917.
24. Liao A, Broeg K, Fox T, et al . Therapeutic effi cacy of FTY720 in a rat model of NK-cell leukemia . Blood 2011; 118 : 2793 - 2800.
25. Fox TE, Bewley MC, Unrath KA, et al . Circulating sphingolipid biomarkers in models of type 1 diabetes . J Lipid Res 2011; 52: 509- 517.
26. Ryland LK, Fox TE, Liu X, et al . Dysregulation of sphingolipid metabolism in cancer . Cancer Biol Ther 2011; 11 : 138 - 149.
27. Jiang Y, DiVittore NA, Kaiser JM, et al . Combinatorial therapies improve the therapeutic effi cacy of nanoliposomal ceramide for pancreatic cancer . Cancer Biol Ther 2011; 12 : 57 - 585.
28. Liao A, Broeg K, FoxT, et al . Therapeutic effi cacy of FTY720 in a rat model of natural killer cell leukemia . Blood 2011; 118 : 2793 - 2800.
29. Di Paola M, Cocco T, Lorusso M . Ceramide interaction with the respiratory chain of heart mitochondria . Biochemistry 2000; 39 : 6660 - 6668.
30. Garcia-Ruiz C, Colell A, Mari M, et al . Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species . Role of mitochondrial glutathione. J Biol Chem 1997; 272 : 11369 - 11377.
31. Hildeman DA, Mitchell T, Aronow B, et al . Control of Bcl-2 expression by reactive oxygen species . Proc Natl Acad Sci USA 2003; 100 : 15035 - 15040.
32. Li D, Ueta E, Kimura T, et al . Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination . Cancer Sci 2004; 95 : 644 - 650.
33. K ozopas K M, Y ang T, B uchan H L, et a l. M CL1, a gene expressed in programmed myeloid cell diff erentiation, has sequence similarity to BCL2 . Proc Natl Acad Sci USA 1993; 90 : 3516 - 3520.
34. Sato T, Hanada M, Bodrug S, et al . Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994; 91 : 9238 - 9242.
35. Yang T, Kozopas KM, Craig RW . The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2 . J Cell Biol 1995; 128 : 1173 - 1184.
36. E pling-Burnette P K, L iu J H, C atlett-Falcone R, et a l. I nhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression . J Clin Invest 2001; 107 : 351 - 362.
37. Shabbits JA, Mayer LD . Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro . Biochim Biophys Acta 2003; 1612 : 98 - 106.
38. Khazanov E, Priev A, Shillemans JP, et al . Physicochemical and biological characterization of ceramide-containing liposomes: Paving the way to ceramide therapeutic application . Langmuir 2008; 24 : 6965 - 6980.
39. Tokudome Y, Saito Y, Sato F, et al . Preparation and characterization of ceramide-based liposomes with high fusion activity and high membrane fl uidity. Colloids Surf B Biointerfaces 2009; 73: 92- 96.
40. Lavie Y, Cao H, Volner A, et al . Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells . J Biol Chem 1997; 272: 1682- 1687.
41. Liu Y, Xie KM, Yang GQ, et al . GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line . Cancer Chemother Pharmacol 2010; 66: 433- 439.
42. Novgorodov SA, Wu BX, Gudz TI, et al . Novel pathway of ceramide production in mitochondria: Thioesterase and neutral ceramidase produce ceramide from sphingosine and acyl-CoA. J Biol Chem 2011; 286 : 25352 - 25362.
43. K roemer G, D allaporta B, R esche-Rigon M . The mitochondrial death/life regulator in apoptosis and necrosis . Annu Rev Physiol 1998; 60 : 619 - 642.
44. K roemer G, G alluzzi L, B renner C. M itochondrial membrane permeabilization in cell death . Physiol Rev 2007; 87: 99- 163.
45. Nica AF, Tsao CC, Watt JC, et al . Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK . Cell Cycle 2008; 7: 3362- 3370.